Vicore Pharma AB has carried out a private placement of shares through an accelerated book building procedure performed by DNB Markets, Pareto Securities and Zonda Partners, raising SEK 185 million before transaction costs.
The private placement generated a large interest and involved both Swedish and international institutional investors, including the Second Swedish National Pension Fund (AP2), the Fourth Swedish National Pension Fund (AP4), Handelsbanken Fonder, HBM Healthcare Investments AG and Swedbank Robur Fonder.
Vicore Pharma is a rare disease pharmaceutical company focused on rare lung disorders and related indications. Vicore Pharma intends to use the issue proceeds to finance (i) preparations for a pivotal study of VP01 in Idiopathic Pulmonary Fibrosis (IPF), development of a commercial formulation and production related activities, (ii) preparations for a pivotal study of VP01 in COVID-19, (iii) the acceleration of the development of follow-on molecules to VP01 through funding of preclinical development and a Phase I study (healthy volunteers), and (iv) general corporate purposes in order to prolong the time period before the company may require additional funding until the second quarter of 2023.
DNB Markets, Pareto Securities and Zonda Partners acted as Joint Bookrunners in connection with the transaction. Baker McKenzie acted as legal advisor to the Joint Bookrunners with a team consisting of Joakim Falkner, Ian Gulam and Marlene Wiklund.